Author(s): Sheryl Stevenson
Alcon’s announcement of the FDA approval for its acoltremon ophthalmic solution 0.003% (Tryptyr; formerly AR-15512) for the treatment of signs and symptoms of dry eye disease (DED)1,2 brings to market a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production. This approval is supported by two phase 3 clinical trials (COMET-2 and COMET-3) evaluating more than 930 patients (randomly assigned 1:1 to acoltremon or vehicle) with a history of DED.1,2
The Eye Care Network reached out to members of the eye care community who specialize in treating DED for their perspectives on this new therapeutic option.
“Those of us who care for patients with dry eye and ocular surface disease know how much these conditions can impact quality of life and are glad to see new therapies being developed to help patients who haven’t responded adequately to currently available therapies,” said Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine; the William Holland Wilmer Professor of Ophthalmology at Johns Hopkins School of Medicine; and co–chief medical editor of Ophthalmology Times®……
Read more: rb.gy/hmo4oj
Source: Ophthalmology Times